ProKidney (PROK) Competitors $3.22 +0.17 (+5.57%) Closing price 07/23/2025 04:00 PM EasternExtended Trading$3.20 -0.03 (-0.78%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PROK vs. KRYS, AKRO, ADMA, RNA, ZLAB, MRUS, SRRK, ACLX, PTCT, and ACADShould you be buying ProKidney stock or one of its competitors? The main competitors of ProKidney include Krystal Biotech (KRYS), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), Avidity Biosciences (RNA), Zai Lab (ZLAB), Merus (MRUS), Scholar Rock (SRRK), Arcellx (ACLX), PTC Therapeutics (PTCT), and ACADIA Pharmaceuticals (ACAD). These companies are all part of the "pharmaceutical products" industry. ProKidney vs. Its Competitors Krystal Biotech Akero Therapeutics ADMA Biologics Avidity Biosciences Zai Lab Merus Scholar Rock Arcellx PTC Therapeutics ACADIA Pharmaceuticals Krystal Biotech (NASDAQ:KRYS) and ProKidney (NASDAQ:PROK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership. Which has more risk & volatility, KRYS or PROK? Krystal Biotech has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500. Comparatively, ProKidney has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Does the media prefer KRYS or PROK? In the previous week, Krystal Biotech had 5 more articles in the media than ProKidney. MarketBeat recorded 11 mentions for Krystal Biotech and 6 mentions for ProKidney. ProKidney's average media sentiment score of 0.77 beat Krystal Biotech's score of 0.73 indicating that ProKidney is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProKidney 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is KRYS or PROK more profitable? Krystal Biotech has a net margin of 37.17% compared to ProKidney's net margin of 0.00%. Krystal Biotech's return on equity of 14.64% beat ProKidney's return on equity.Company Net Margins Return on Equity Return on Assets Krystal Biotech37.17% 14.64% 13.28% ProKidney N/A N/A -15.03% Do institutionals & insiders have more ownership in KRYS or PROK? 86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 51.6% of ProKidney shares are held by institutional investors. 13.7% of Krystal Biotech shares are held by insiders. Comparatively, 41.5% of ProKidney shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts recommend KRYS or PROK? Krystal Biotech presently has a consensus price target of $211.33, indicating a potential upside of 37.90%. ProKidney has a consensus price target of $6.25, indicating a potential upside of 94.10%. Given ProKidney's higher possible upside, analysts clearly believe ProKidney is more favorable than Krystal Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Krystal Biotech 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00ProKidney 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Which has stronger earnings & valuation, KRYS or PROK? Krystal Biotech has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKrystal Biotech$290.52M15.24$89.16M$4.1636.84ProKidney$80K11,781.18-$61.19M-$0.60-5.37 SummaryKrystal Biotech beats ProKidney on 12 of the 17 factors compared between the two stocks. Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PROK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PROK vs. The Competition Export to ExcelMetricProKidneyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$892.73M$2.43B$5.57B$9.42BDividend YieldN/A1.80%4.05%3.99%P/E Ratio-5.379.1428.0920.08Price / Sales11,781.18540.89403.9184.07Price / CashN/A166.9336.1958.45Price / Book-0.945.168.615.83Net Income-$61.19M$30.99M$3.24B$258.27M7 Day Performance-8.52%3.81%3.53%2.69%1 Month Performance399.07%12.26%10.99%12.91%1 Year Performance53.33%0.95%35.43%21.81% ProKidney Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PROKProKidney3.431 of 5 stars$3.22+5.6%$6.25+94.1%+37.6%$892.73M$80K-5.373KRYSKrystal Biotech4.9192 of 5 stars$150.08+1.6%$213.75+42.4%-26.0%$4.34B$333.45M36.08210Analyst ForecastAKROAkero Therapeutics3.8123 of 5 stars$53.60+3.6%$82.50+53.9%+86.5%$4.27BN/A-27.4930Positive NewsADMAADMA Biologics3.8974 of 5 stars$17.69-1.6%$27.67+56.4%+25.0%$4.22B$426.45M20.81530Positive NewsRNAAvidity Biosciences2.5265 of 5 stars$33.53+5.8%$66.35+97.9%-26.2%$4.04B$10.90M-11.18190Gap UpZLABZai Lab3.5019 of 5 stars$35.47+0.8%$54.28+53.0%+92.7%$3.94B$398.99M-14.241,869Positive NewsGap UpMRUSMerus2.1123 of 5 stars$56.51+2.8%$84.64+49.8%+15.5%$3.91B$54.73M-13.8537Upcoming EarningsSRRKScholar Rock3.4049 of 5 stars$41.15+6.2%$42.67+3.7%+331.6%$3.91BN/A-16.26140Analyst RevisionACLXArcellx2.5638 of 5 stars$70.70+3.7%$111.23+57.3%+10.8%$3.90B$107.94M-23.6580News CoveragePositive NewsPTCTPTC Therapeutics4.3838 of 5 stars$48.14+0.8%$65.00+35.0%+40.3%$3.82B$1.77B7.391,410Positive NewsACADACADIA Pharmaceuticals4.1892 of 5 stars$22.55+2.5%$27.88+23.6%+27.9%$3.77B$996.28M16.46510Positive News Related Companies and Tools Related Companies KRYS Alternatives AKRO Alternatives ADMA Alternatives RNA Alternatives ZLAB Alternatives MRUS Alternatives SRRK Alternatives ACLX Alternatives PTCT Alternatives ACAD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PROK) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBitcoin just humbled Jeff BezosBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PROK Stock Alerts